Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Abstract Background We evaluated the antitumor activity and safety of avelumab, a human anti–PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy. Methods...

詳細記述

保存先:
書誌詳細
主要な著者: Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do-Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun-Wook Lee, Jeffrey R. Infante, Sung Sook Lee, Margaret Kemeny, Ulrich Keilholz, Bohuslav Melichar, Alain Mita, Ruth Plummer, Denis Smith, Arnold B. Gelb, Huiling Xiong, Janet Hong, Vikram Chand, Howard Safran
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Publishing Group 2019-02-01
シリーズ:Journal for ImmunoTherapy of Cancer
主題:
Avelumab
Metastatic
Gastric
Esophagogastric junction
Adenocarcinoma
Maintenance
オンライン･アクセス:http://link.springer.com/article/10.1186/s40425-019-0508-1
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料